Genetic testing results were available for <45 patients (<10%), and a mutation in the bone morphogenetic protein receptor type II gene was present in 12 (5%, about 40% of tested) of PAH patients and <5 of CTEPH patients (tested because of relatives with known mutations, for example). The gene discussed is BMPR2; the disease is pulmonary arterial hypertension.